Tuesday, July 07, 2020 12:46:07 AM
With CYDY I think for the first time in my career I have truly seen the stars align.
Let me begin by saying I am NOT a savvy investor with formal investment training, access to the best financial firms or legions of analysts from B-school. Therefore, my decision to invest rests HEAVILY on the science itself. So far, it has served me well.
Leronlimab truly is a gem of a drug, which without exaggeration could end a pandemic, revive economies, and alter the course of modern medicine. However, I think most of us are unable to visualize the extent of its possible impact. Imagine asking Alexander Fleming how his mouldy petri dish would change the world. This drug very well may be to T cell mediated / autoimmune processes what penicillin is to bacterial diseases.
The usage of leronlimab to treat the auto inflammatory state triggered by covid was a stroke of genius. I think Dr. Seethamraju was brilliant in using this therapy, and I think Dr. Bruce Patterson's team was brilliant in recognizing the marked elevation of RANTES (the CCR5 ligand) in these patients.
What absolutely sold me on the mechanism of action was the fact that out of curiosity I decided to question the other findings of COVID-19. What about those kids with the Kawasaki-type syndromes? what about those mysterious petechial rashes?
I did my own research on PubMed and guess what? There is plenty of evidence from the early 2000s and before, that RANTES is significantly elevated in Kawasaki's disease. Guess what else i'ts elevated in? Henoch-Schonlein purpura.
The fact that the elevated RANTES was identified independently of this association with a kawasaki-type syndrome, really brings it home for me.
Lastly, if this is true, then Kawasaki syndrome and HSP are both likely triggered by a viral insult, which then results in upregulation in RANTES production and the recruitment of T cells to the area and resultant overproduction of inflammatory molecules.
Many autoimmune conditions are likely a combination of genetic predisposition coupled with a viral or environmental trigger. The reason why most people aren't grasping the magnitude of this discovery is because they don't realize the sheer number of auto-immune processes which up until now have had no clear trigger, and no real clear mechanism by which to treat safely and effectively.
I am absolutely a believer in the science, and only the science. Do your own research, but drugs like this don't come often. I hope its the real deal and some unforeseen political force doesn't keep it from realizing its full potential.
Really appreciate everyones thoughtful commentary on this board.
Recent CYDY News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 09:15:10 PM
- Form SC TO-I - Tender offer statement by Issuer • Edgar (US Regulatory) • 06/03/2024 09:10:56 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/06/2024 09:17:30 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/06/2024 09:16:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 09:09:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2024 02:30:20 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:16:47 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:15:34 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/22/2024 10:16:11 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/22/2024 05:15:08 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 02:00:24 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 10:31:57 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/29/2024 10:22:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2024 01:40:14 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/19/2024 10:15:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/16/2024 10:16:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:04:57 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:04:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:02:59 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:02:30 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM